ACOS and Avedro, Inc. Announce Initiation of a Phase 3 Study on Accelerated Corneal Cross-Linking

WALTHAM, Mass.--(BUSINESS WIRE)--ACOS (The American-European Congress of Ophthalmic Surgery) and Avedro, Inc. jointly announced today the initiation of a Phase 3, multi-center, randomized, controlled evaluation to study accelerated corneal collagen cross-linking in eyes with keratoconus or corneal ectasia after refractive surgery. ACOS is sponsoring the study, which will be conducted in 100 clinical centers across the United States. Each of the 100 clinical sites will use Avedro’s KXL™ System and VibeX™ (riboflavin ophthalmic solution) to treat all patients enrolled in the study.